Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study of Nintedanib and Capecitabine in Refractory Metastatic Colorectal Cancer

NCT02393755 is registered in ClinicalTrials.gov with Roswell Park Cancer Institute as lead sponsor.

NCT NCT02393755
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02393755 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study of Nintedanib and Capecitabine in Refractory Metastatic Colorectal Cancer
Lead sponsor
Roswell Park Cancer Institute
Phase
Phase 1/2
Overall status
Completed
Start date
May 8, 2015
Completion date
May 18, 2021
Enrollment
42 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

colon adenocarcinoma, rectal adenocarcinoma, recurrent colon carcinoma, recurrent rectal carcinoma, stage iva colon cancer, stage iva rectal cancer, stage ivb colon cancer, stage ivb rectal cancer